

Amendments to the Specification:

Please replace the paragraph beginning on page 1 at line 6 under the heading "Cross Reference to Related Applications" with the following amended paragraph:

This application is a continuation of application Serial No. 08/950,542, filed October 15, 1997; which is a continuation of application Serial No. 08/459,654, filed June 2, 1995, now abandoned; which is a divisional of application Serial No. 08/093,302, filed July 15, 1993, now issued as U.S. Patent 5,462,928; which is a continuation of application Serial No. 07/781,552, filed October 22, 1991, now abandoned in part of U.S. Application Serial No. 07/510,274, filed April 14, 1990.

Please replace the paragraph beginning on page 10 at line 1 with the following amended paragraph:

Referring to Fig. 1, the starting compound I is 4-bromo-1-chlorobutyl boronate pinacol and is prepared essentially by the procedure of Matteson et al. (*Organometallics* 3:1284, 1984), except that a pinacol ester is substituted for the pinanediol ester. Similar compounds such as boropiecolic acid and 2-azetidine boronic acid can be prepared by making the appropriate selection of starting material to yield the pentyl and propyl analogs of compound I. Further, Cl can be substituted for Br in the formula, and other diol protecting groups can be substituted for pinacol in the formula, e.g., 2,3-butanediol and alpha-pinanediol.

Please replace the paragraph beginning on page 10 at line 12 with the following amended paragraph:

Compound II is 4-bromo-1[(bistrimethylsilyl) amino] butyl boronate pinacol is prepared by reacting compound I with $[(CH_3)_3O_3Si]_2N-Li^+$. In this reaction hexamethyldisilazane is dissolved in tetrahydrofuran and an equivalent of n-butyllithium added

at -78°C. After warming to room temperature (20°C) and cooling to -78°C, an equivalent of compound I is added in tetrahydrofuran. The mixture is allowed to slowly come to room temperature and to stir overnight. The alpha-bis[trimethylsilane]-protected amine is isolated by evaporating solvent and adding hexane under anhydrous conditions. Insoluble residue is removed by filtration under a nitrogen blanket, yielding a hexane solution of Compound II.

Please replace the paragraph beginning on page 10 at line 24 with the following amended paragraph:

Compound III is 1-trimethylsilyl-boroProline-pinacol, the ~~N-trimethylsilyl~~ N-trimethylsilyl protected form of boroProline is obtained by the thermal cyclization of compound II during the distillation process in which compound II 2 is heated to 100-150°C and distillate is collected which boils 66-62°C at 0.06-0.10 mm pressure.

Please replace the originally filed Abstract with the following paragraph:

Peptide inhibitors of dipeptidyl-aminopeptidase type IV (DP-IV) are provided. The peptide inhibitors have an isomeric purity of about 96-99 percent. The peptide inhibitors include one or more amino acids covalently coupled to boroproline moiety. The compounds are useful DP-IV inhibitors, *in vivo* and *in vitro*.